<DOC>
	<DOCNO>NCT00450307</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , 3F8 , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Colony-stimulating factor , GM-CSF , may increase number immune cell find bone marrow peripheral blood . Giving monoclonal antibody therapy together GM-CSF may effective treatment neuroblastoma . PURPOSE : This phase I trial study side effect best dose monoclonal antibody 3F8 give together GM-CSF treat young patient high-risk , refractory relapse neuroblastoma .</brief_summary>
	<brief_title>Monoclonal Antibody 3F8 GM-CSF Treating Young Patients With High-Risk , Refractory Relapsed Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose monoclonal antibody 3F8 administer sargramostim ( GM-CSF ) young patient high-risk , refractory relapse neuroblastoma . - Assess anti-neuroblastoma effect regimen patient . OUTLINE : This open-label , dose-escalation study monoclonal antibody 3F8 . Patients receive sargramostim ( GM-CSF ) subcutaneously daily day -5 11 monoclonal antibody 3F8 IV 30 minute day 0-4 7-11 . Treatment repeat every 4-6 week 2 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos monoclonal antibody 3F8 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must diagnosis NB define international criteria,45 i.e. , histopathology ( confirm MSKCC Department Pathology ) BM metastases plus high urine catecholamine level . Patients must refractory relapsed highrisk NB ( include MYCNamplified stage 3/4/4S MYCNnonamplified stage 4 &gt; 18 month old ) resistant standard therapy . Prior treatment 3F8 allow . Age &lt; 21 year . Signed informed consent indicate awareness investigational nature program . Existing major organ dysfunction grade 2 less , exception myelosuppression ( neutrophil count &gt; 500/ul platelet count &gt; 10,000/ul acceptable ) , alopecia , hear loss . Patient take antihypertensive medication . History allergy mouse protein . Active lifethreatening infection . Human antimouse antibody ( HAMA ) titer &gt; 1000 ELISA units/ml . Prior treatment 3F8 NOT exclusion criterion . Inability comply protocol requirement . Pregnant woman exclude fear danger fetus . Therefore negative pregnancy test require woman childbearing age , appropriate contraception use study period .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
</DOC>